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QOL  quality of life 
DDS  drug delivery system 
NAC  N-acethyl-L-cystein 
TX-100  tritonX-100 
SCT  salmon calcitonin 
PTH  human parathyroid hormone (1–34) 
INS  human insulin 
SGC  sodium glycocholate 
AUC  area under the curve 
SD  standard deviation 
S.C.  subcutaneous injection 
I.V.  intravenous injection 
MW  molecular weight 
HCO  hydrogenated castor oil 
CaCO3  calcium carbonate 
Laureth-25 polyoxyethylene (25) lauryl ether 
FITC  fluorescein isothiocyanate 
FD-4  FITC-dextran 4kDa 
Laureth-9  polyoxyethylene (9) lauryl ether 
HPLC  high performance liquid chromatography 
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Fig. 3. The chemical structure of N-Acetyl-L-Cystein (NAC) 
 





Formulation-L?SCT????????? 2??????? 50 ng/ml??????
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Formulation-LN? SCT? NAC???????????????????????
???? 15.7%????Formulation-L? 2???????????? NAC???
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Fig. 4. Comparison of plasma concentration ?  time profiles following nasal 
administration of liquid and powder formulations, and subcutaneous administration 
(?) of 0.1 mg of salmon calcitonin in rats.  
?; Formulation-L (liquid formulation with SCT in saline), ?; Formulation-LN (liquid 
formulation with SCT and NAC in saline), ?; Formulation-P (powder formulation with 
SCT and ethylcellulose), ?; Formulation-PN (powder formulation with SCT, NAC and 
ethylcellulose).  
Data represent mean plasma concentrations of salmon calcitonin ± SD (n = 4-5). 
 
Table 1. Bioavailabilities of salmon calcitonin after nasal administration of liquid 
and powder formulations, and subcutaneous administration containing 0.1 mg of 































15.7 ± 4.0 a
11.9 ± 8.4
30.0 ± 8.6 b, c, d
47.3 ± 7.7
100.0 ± 16.4
Data represent the mean ± SD (n = 4-5).
Statistical analysis was performed using Student’s t test. a P < 0.05 versus Formulation-L. b P <




 ?40, 41?? 0.15 mg?? SCT?????????????????? NAC??
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Fig. 5. Comparison of plasma concentration ? time profiles of salmon calcitonin 
following nasal administration of powder formulations containing NAC (?) or 
sodium glycochorate (?) in rats.  




??????????????????? 7.7% ± 2.1% (n = 5)????????NAC
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Fig. 6. Comparison of plasma concentration ? time profiles of salmon calcitonin 
following nasal administration of powder formulations containing NAC (?) or 
Miacalcin (?) in rats.  
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Formulation-L? 2 ??????????????????Fig. 7????????
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Fig. 7. Comparison of plasma concentration ?  time profiles following nasal 
administration of liquid and powder formulations, and subcutaneous administration 
(?) of 0.3 mg of salmon calcitonin in dogs.  
?; Formulation-L, ?; Formulation-PN.  




 Table 2. Bioavailabilities of salmon calcitonin after nasal administration of liquid 
and powder formulations, and subcutaneous administration containing 0.3 mg of 























24.9 ± 3.5 a
50.9 ± 15.4
100.0 ± 17.2
Data represent the mean ± SD (n = 4).























































Fig. 8. Comparison of plasma concentration – time profiles in rats following nasal 
administration of liquid or powder formulations containing 0.1 mg of human 
parathyroid hormone (1–34). 
? Liquid formulation; ? Powder formulation containing N-acetyl-L-cysteine. 






























Fig. 9. Comparison of plasma concentration – time profiles in rats following nasal 
administration of liquid or powder formulations containing 0.1 mg of human insulin. 
? Liquid formulation; ? Powder formulation containing N-acetyl-L-cysteine. 
Data represent mean plasma concentrations ± SD (n = 7). 
 
Table 3. Bioavailabilities of human parathyroid hormone (1–34) (PTH) or human 
insulin (INS) in rats after nasal administration of liquid and powder formulations 
































28.2 ± 6.5 a
100.0 ± 13.5
10.5 ± 8.9
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Fig. 10. Plasma concentration of calcium in rats following nasal administration of 
powder formulation containing SCT and NAC (?) or saline (?). 


















NAC? 0.15 mg?? 0.25 mg????????? 3???????? 8???















Fig.11. Cross-sectional photographs of nasal cavity in rabbits after the 
administration of SCT powdery formulation. 
Upper; the nasal formulation without NAC was administered for 8 days (control). 
Lower; the nasal formulation containing 0.25 mg of NAC was administered for 8 days. 
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 Table 4. Pathological abnormality in nasal cavity and related tissues or organs after 
multiple nasal administrations of powdery formulation with NAC to rabbits for eight 
consecutive days 
 
N : Negative,   Pos : Positive
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Fig. 12. Possible mechanism for the improved nasal bioavailability of peptide drug 
delivered in a powder formulation with ethylcellulose and N-acetyl-L-cysteine. 
 





























































































Fig. 13. Comparison of plasma concentration ?  time profiles following nasal 
administration of powder formulations containing ethylcellulose (?) or lactose (?) 
filler, 0.1 mg of salmon calcitonin, and absorption enhancer (N-acetyl-L-cysteine, 
NAC; or sodium glycocholate, SGC) in rats. 
Panel A, NAC; panel B, SGC. 
Data represent mean plasma concentrations of salmon calcitonin ± SD (n = 4 or 5). 
 
Table 5. Bioavailabilities of salmon calcitonin in rats after nasal administration of 

























30.0 ± 8.6 a
10.5 ± 4.8
18.0 ± 0.5 b
12.5 ± 1.5
Data represent means ± SD (n = 4 or 5).
Statistical analysis was performed using Student’s t-test. a P < 0.01 versus formulation with 
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Fig. 14. Comparison of plasma concentration ? time profiles in rats following nasal 
administration of powdery formulations with various water-insoluble fillers: 
ethylcellulose (?), hydrogenated castor oil (?), talc (?), calcium carbonate (?), 
crystalline cellulose (?), or Microcelac (?). Each formulation contained 0.1 mg of 
salmon calcitonin and 1.5 mg of N-acetyl-L-cysteine. 
Data represent mean plasma concentrations of salmon calcitonin ± SD (n = 4 or 5). 
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Table 6. Bioavailabilities of salmon calcitonin in rats after nasal administration of 


























Data represent means ± SD (n = 4 or 5).
Statistical analysis was performed using Student’s t-test. a P < 0.01 versus Microcelac. b P < 0.05 











29.7 ± 9.5 a,c
21.7 ± 9.2 b
23.3 ± 4.0 a
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Fig. 15. Influence of water absorbability of filler in the powder formulation on nasal 
bioavailability of salmon calcitonin. 
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0.10 mg?0.15 mg?? 0.25 mg?????? 5?? SCT?1.0 mg/dose??????
???????????????????????NAC???????????
??????????????NAC?? 1.5mg???????????????
?? 35%????????Fig. 16??  
 
 













































Fig. 16. Influence of NAC amount in the powder formulation on nasal bioavailability 
of salmon calcitonin.  
Data represent the mean absolute bioavailabilities of salmon calcitonin ± SD (n = 4). 
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 ? 3?? ???????? 
? SCT??????????????????????????????? 76 µm
???????????45 µm???75–106 µm?? 150–250 µm? 3?????
???????????????????????????????????SCT
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Table 7. Bioavailabilities of salmon calcitonin after nasal administration of powder 
























28.6 ± 9.5  
22.0 ± 6.1



























































Fig. 17. The chemical structure of polyoxyethylene (C25) lauryl ether (Laureth-25) 
 























































































Fig. 18. Comparison of plasma concentration – time profiles following nasal 
administration of various aqueous formulations containing 2.5 mg of FD-4.  
?; Formulation-C (saline solution of FD-4), ?; Formulation-L (saline solution of FD-4 
containing Laureth-25), ?; Formulation-N (saline solution of FD-4 containing NAC), 
?; Formulation-LN (saline solution of FD-4 containing NAC and Laureth-25).  




 Table 8. Bioavailabilities of FD-4 after nasal administration of various aqueous 

































40.0 ± 5.5 a, b, c
100.0 ± 6.0
Data represent the mean ? SD (n = 4).
Statistical analysis was performed using Student’s t test. a P < 0.01 versus Formulation-C.
b P < 0.01 versus Formulation-N. c P < 0.05 versus Formulation-L. 
Laureth-25
Laureth-25
? Laureth-25??? 5%??????NAC??????????? FD-4????
??????????? Fig. 19???NAC??? 5%?????Laureth-25??






??????? 40%???????????? NAC ? Laureth-25 ??????
????????????????????????????????????
??????NAC ? Laureth-25 ???????????????1% NAC ? 1% 
Laureth-25????????????????????? 9.9% ± 6.5%????2% 































































Fig. 19. Influence of NAC concentration in the formulation on nasal bioavailability 
of FD-4 at a fixed Laureth-25 concentration of 5%. 













































Fig. 20. Influence of Laureth-25 concentration in the formulation on nasal 
bioavailability of FD-4 at a fixed NAC concentration of 5%. 
























18.7% ± 2.7% (n = 4)????5% NAC? 1% Laureth-25????????????
?????? 19.7% ± 6.6% (n = 4)?????????? 
? ????NAC?Laureth-25????????????????????SCT??
?????????????®??????5 µl???????®?10 µg SCT??
????????????????SCT??????? 2???????????
????Fig. 22?????????????? 7.7% ± 2.1% (n = 4)????????
??? 10 µg SCT? 5% NAC? 1% Laureth-25????????????????




































Fig. 21. Comparison of plasma concentration – time profiles following nasal 
administration of various aqueous formulations containing 0.1 mg of salmon 
calcitonin.  
?; Formulation-C, ?; Formulation-L, ?; Formulation-N, ?; Formulation-LN.  
Data represent mean plasma concentrations of salmon calcitonin ± SD (n = 4) 
 
Table 9. Bioavailabilities of salmon calcitonin after nasal administration of various 






























15.7 ± 4.0 a
12.3 ± 2.5 a
20.6 ± 7.4 a
100.0 ± 16.4
Data represent the mean ? SD (n = 4).


















































Fig. 22. Comparison of plasma concentration ? time profiles of salmon calcitonin 
following nasal administration of powder formulations containing NAC (?) or 
Miacalcin (?) in rats.  
Data represent mean plasma concentrations of salmon calcitonin ± SD (n = 4). 
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Fig. 23? Laureth-25??? 3??????????????????????
?????Laureth-9? 0.01%??????????? 100%??????????
???????? 0.05%????????? 0.2%?????? 100%??????
?????????Laureth-25? 5%?????????????????????
?????? Laureth-25 ?????????????????????????



























































Fig. 23. Hemolytic activity – concentration profiles of various surfactants in saline.  
?; Laureth-9, ?; Deoxycholate Sodium, ?;Glycocholate Sodium, ?; Laureth-25. 
 
Table 10. Release of phospholipids from mucous membranes after nasal 





27.4 ± 6.9 a
16.0 ± 2.8 b
Saline
1% deoxycholate sodium
1% Laureth-25 + 5% NAC
Data represent the mean ? SD (n = 6).
Statistical analysis was performed using Student’s t test.
a P < 0.01 versus Saline. b P < 0.01 versus 1% deoxycholate sodium. 
D oxycholate Sodium
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?????????????? 9.8%?n=5?????????????????
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(2) PTH?? INS 
????? 1.0 mg? PTH?? INS? 27.5 mg?????????? 1.5 mg?
NAC??????????????????????????????????































??????????????????????????? 100 µl????12,000 
rpm ? 3 ???????????????????????????????
−20 °C?????????????????????????????????
????????SCT?0.31 ng/ml?PTH?1.6 ng/ml?INS?10 µU/ml??????






















Fig. 25. Hand-made nasal powder device used for rat administration study 
(1) Polyethylene tube, (2) Three-way cock, (3) Pipette tip, (4) Plastic syringe (1 ml) 
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 (2) ???? 
? ?? 13 kg?? 15 kg?????????Kitayama Labs?? 20???????
??????????????? 40 mg/kg?????????????????
????????????9 mg??????SCT??? 0.3 mg???Pfeiffer??
















Fig. 26. Bi-Dose Nasal Powder device for nasal  



















? ????? 3??????????????2????????0.15?? 0.25 mg

















? 10 mg?SCT???????????3?7??? 300 µl??90 mg????????
????????HCO?????CaCO3??????????????????















? ?? 200 g?? 250 g?Wistar???????Nippon SLC?? 20??????
?????????????????? 50 mg/kg??????????????
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 ??? 1????????????????????????? 3 mg?SCT??
? 0.1 mg????????????????????????????????













? ???????? Takeda?????57??????????Fig. 27??????
???????????? 2.1 cm??? 7.8 cm???????????????



















Fig. 27. Measurement of water absorption speed of powder 
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 ? III?? ???? 
?????? 
FITC ???????FD-4?? Sigma-Aldrich ???????????????
??25??????????Laureth-25????????????9??????
????Laureth-9?? Nikko Chemicals???????????????????








???Formulation-C ???????????????????????? 25 mg








? ?? 200 g?? 250 g?Wistar???????Nippon SLC?? 20???????
????????????????? 50 mg/kg????????????????
? 1??????????????????????????? 5 µl?FD-4??
? 2.5 mg? SCT??? 0.1 mg???????????????????????
??????????????????®10 µl ?SCT??? 10 µg???????
?????????????????????????50 mg/kg?????FD-4
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 ?? 0.1 mg?SCT????????????????????????????
?????? 100 µl????12,000 rpm? 3?????????????????
??????????????−20 °C???????? 
 
???? FD-4?? SCT?????? 
? FD-4?????????20 µl???????? 680 µl? 0.1 N???????
??????????????? FD-4?????????????495 nm???
?? 515 nm?????? SCT????????????????????????
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